Austria : The ocular conjunctiva as a mucosal immunization route

The present invention specifically provides a novel vaccine formulation suitable for ocular immunization and provides a method for inducing a local and systemic immune response. Immunization via the conjunctiva with TTd plus wBP adjuvant resulted in a 33% survival rate of challenged mice compared to a 0% survival rate in non-immunized animals


Innovations offered:

  • Needle-free vaccine administration strategy
  • Most effective means of inducing an immune response
  • Local exposure to an antigen results in much higher levels of specific SIgA and an associated mucosal immunologic memory in the region of exposure than in distant sites (Holmgren et al, Curr Opin. Immunol., 2012, 24(3))
  • In addition to IgA responses, mucosal vaccination induces systemic IgG responses that represent a further defence against invasion by microorganisms
  • In addition to serum IgG and mucosal IgA antibodies, mucosal immunization can stimulate cell mediated responses including helper CD4+ T cells and CD8+ cytotoxic T lymphocytes, the latter being important to combat intracellular pathogens.








Preferred Cooperation:

□ Commercial Agreement with technical assistance

R Technical Cooperation Agreement

□ Financial Investment Agreement

□ Joint Venture

R Licensing Agreement

□ Manufacturing Agreement

□ Research Collaboration Agreement

□ Services Agreement


Type of Partner sought: